The Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market is expected to reach a value of US$ 3.3 billion in 2023 and US$ 6.2 billion by 2033. A CAGR of 6.6% is anticipated for the market over the forecast period.
Market expansion is fueled by the escalating enzyme deficits and lysosomal storage diseases as Gaucher, Pompe, and Fabry. The market size is being driven by rising patient awareness of the need to use Pompe disease treatment more frequently. The need for enzyme replacement therapy (ERT) for Gaucher and Pompe disorders is also rising due to the prevalence of metabolic diseases, toxic body cells, and uncommon diseases.
Unleash the power of knowledge and transformation by accessing our Sample Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-12771
Healthcare manufacturers are indulged in developing advanced enzyme replacement therapy treatments that influence market opportunities. Several life-threatening chronic diseases are increasing the demand for Gaucher disease diagnosis by healthcare providers. In addition, growing economies, the medical tourism industry, and huge investments are bolstering market opportunities.
According to a report published by National Fabry Foundation, in May 2020, around 7,713 people suffered from Fabry disease in the United States. Similarly, in August 2021, according to a report by the National Institute of Neurological Disorders and Stroke, nearly 40,000 people suffered from Pompe disease in the United States.
High Treatment Costs Hamper the Market Growth:
The availability of treatment resources for rare disorders is fueling market growth. Conversely, the increasing treatment and therapy costs and lack of skilled professionals limit the market growth. Moreover, the availability of alternative or low-cost solutions and therapies is restraining the market growth.
Reach Out To Our Analyst And Get All Your Queries Answered! https://www.futuremarketinsights.com/ask-question/rep-gb-12771
Key Takeaways:
- The Gaucher and Pompe diseases enzyme replacement therapy (ERT) market is expected to have a valuation of US$ 6.2 billion by 2033.
- With a CAGR of 6.6%, the global market is increasing during the forecast period.
- The market in the United States is anticipated to capture 6.1% of the CAGR through 2033.
- The United Kingdom Gaucher and Pompe diseases enzyme replacement therapy (ERT) market is expected to thrive at a CAGR of 6.9% during the forecast period.
- China market is expected to secure a CAGR of 7.1% over the forecast period.
- Canada market may capture a CAGR of 6.9% by 2033.
Who is Winning?
Key players focus on patients’ requirements and launching innovative products to improve their health. Research and development in advanced therapy treatment equipment for patients for a better quality of life with compelling results may drive market growth.
Players upsurge the market size through marketing methodologies, including agreements, collaborations, partnerships, product launches, mergers, and acquisitions.
Other Prominent Players in the Global Market:
- Alexion Pharmaceuticals, Inc.
- Pfizer
- BioMarin Pharmaceuticals Inc
- Ultragenyx Pharmaceutical Inc.
- Janssen Pharmaceuticals, Inc (J&J)
- Sigma-Tau Pharmaceuticals Inc,
- AbbVie Inc.
- Sanofi S.A.
- Shire Plc
- Merck KGaA
- Takeda Pharmaceuticals
Personalized Experiences Redefined: Our Customization Report Holds the Answers! https://www.futuremarketinsights.com/customization-available/rep-gb-12771
Recent Developments in the Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market are:
- In November 2019, according to National Center for Biotechnology Information, Brineura launched enzyme replacement therapy for Neuronal Ceroid Lipofuscinosis Type 2 Disorder.
- In September 2021, Takeda Pharmaceutical Company partnered with JCR Pharmaceuticals Company for hunter syndrome treatment in the United States.
Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market by Category:
By Therapeutic Condition:
- Gaucher Disease:
- Type 1 (Non-neuropathic)
- Type 2 (Acute Infantile Neuronopathic)
- Type 3 Gaucher Disease (Chronic Neuronopathic)
- Perinatal Lethal Gaucher Disease
- Cardiovascular Gaucher Disease:
- Pompe Disease
- Classic Infantile-onset
- Late-onset
By Route of Administration:
- Oral
- Parental
By Distribution Channel:
- Hospital Pharmacies
- Specialty Treatment Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- South Asia & Pacific
- East Asia
- The Middle East & Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube